On July 23, 2024, the Association of Cannabinoid Specialists was joined by ACS President and Founder Jordan Tishler, MD as he discussed minor cannabinoids, terpenes, and their potential uses.
The talk comprised two main sections: minor cannabinoids and terpenes. For cannabinoids, Dr. Tishler discussed various compounds like CBG, CBC, CBDA, Delta-8 THC, THCV, THCA, and CBN, emphasizing their preclinical study results and potential therapeutic benefits, including anti-inflammatory, anti-cancer, anti-convulsant, and neuroprotective effects. He underscored that while these findings are promising, they are mostly based on preclinical data, and more human trials are needed before these compounds can be recommended for medical use.
The terpenes section covered compounds like beta-caryophyllene, myrcene, limonene, alpha-pinene, linalool, eucalyptol, and borneol, outlining their potential effects on pain, anxiety, inflammation, and more. Dr. Tishler highlighted that most research on terpenes is preclinical and that further studies are required to confirm their therapeutic efficacy in humans.
The event concluded with a Q&A session, addressing questions about the safety, dosage, and practical applications of cannabis-related treatments. The presentation emphasized the need for better regulation and more scientific research to inform clinical practices.
ACS courses on Minor Cannabinoids and Terpenes are available here.